

RECEIVED
CENTRAL FAX CENTER

NOV 22 2004



901 California Avenue Palo Alto, CA 94304-1104 Main: 650 • 496-6400 FAX: 650 • 498-1200

FAX TRANSMITTAL SHEETNO. OF PAGES (including this page): 7

TO: I. Ouspenski
Art Unit: 1644
FAX: (703) 872-9306
FROM: Sheela Mohan-Peterson

DATE: November 22, 2004

RE: Docket No.: DX0936KB
USSN: 10/086,972
Filed: 03/01/2002
Title: Novel Uses of Mammalian OX2 Protein and Related Reagents

Any difficulty with this facsimile, please call: Melanie Lyons at (650) 496-1183

Documents attached:

1.	Transmittal	1 page
2.	Response to Notice of Non-compliant Amendment	5 pages

I hereby certify that this correspondence is being facsimile transmitted to the USPTO to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on
November 22, 2004

A handwritten signature in cursive script, appearing to read "Melanie Lyons", written over a horizontal line.

Melanie Lyons

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to DNAX which is confidential and/or legally privileged. The information is intended only for the use of the person or entity named above. If you have received this fax in error, please immediately notify us by telephone or return Fax.

RECEIVED
CENTRAL FAX CENTER

NOV 22 2004

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/086,972	
	Filing Date	03/01/2002	
	First Named Inventor	Robert M HOEK	
	Art Unit	1644	
	Examiner Name	I. Ouspenski	
Total Number of Pages In This Submission	7	Attorney Docket Number	DX0936KB


ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks: 1. Response to Notice of Non-Compliant Amendment 2. Fax Transmittal Sheet		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Sheela Mohan-Peterson, Reg. No. 41,201 DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304-1104		
Signature			
Date	22 Nov - 2004 (SMP)		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:			
Typed or printed	Melanie Lyons		
Signature		Date	November 22, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**RECEIVED
CENTRAL FAX CENTER**

Appl. No. 10/086,972
Amdt. dated November 22, 2004
Reply to Office action of October 20, 2004

NOV 22 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re application of:

Robert M. HOEK, *et al.*

Application No.: 10/086,972

Filed: March 1, 2002

For: NOVEL USES OF MAMMALIAN
OX2 PROTEIN AND RELATED
REAGENTS

Examiner: I. Ouspenski

Art Unit: 1644

Conf. No.: 1945

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 22, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

by:


MELANIE LYONS

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT
(37 CFR 1.121)

Honorable Sir:

In response to the Notice of Non-Compliant Amendment dated October 20, 2004, Applicants submit the following response (which response is due November 22, 2004, as November 20, 2004, is a Saturday, and November 21, 2004, is a Sunday). Reconsideration is respectfully considered.

Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.